Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Cash from Financing Activities (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Cash from Financing Activities for 2 consecutive years, with -$27000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities rose 95.3% to -$27000.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $212.7 million, a N/A change, with the full-year FY2025 number at $330.3 million, up 324.91% from a year prior.
  • Cash from Financing Activities was -$27000.0 for Q4 2025 at Kestra Medical Technologies, up from -$1.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $214.7 million in Q2 2025 to a low of -$1.9 million in Q3 2025.